Furthermore, we have confirmed that intra-arterial administration of recombinant HGF induced angiogenesis in a rabbit hindlimb ischemia model (15) and examined the feasibility of gene therapy using HGF to treat peripheral arterial disease rather than recombinant therapy, because of its disadvantages. Here, HGF is linked to peripheral arterial disease.